Examination of treatment utility and advantage of taking medicine in which acknowledgment function improvement in patient with schizophrenia with new antipsychotic is made main axis

Examination of treatment utility and advantage of taking medicine in which acknowledgment function improvement in patient with schizophrenia with new antipsychotic is made main axis - Examination of treatment utility and advantage of taking medicine in which acknowledgment function improvement in patient with schizophrenia with new antipsychotic is made main axis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005025

Enrollment

Registered

2011-03-01

Start date

2011-06-01

Completion date

Unknown

Last updated

2025-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

schizophrenia

Interventions

pharmacotherapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria:

Exclusion criteria

Exclusion criteria: In case of patients with diabetic mellitus is excluded because Olanzapine is contraindicated drug.

Design outcomes

Primary

Measure	Time frame
There is a possibility that the findings obtained by this examination leads to the improvement of QOL and compliance of taking medicine in patients with schizophrenia.	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Feb 4, 2026